Healthequity (HQY) Cash & Equivalents (2013 - 2026)

Healthequity's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $265.4 million for Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 7.82% year-over-year to $265.4 million in Q2 2026; TTM through Apr 2026 was $265.4 million, a 7.82% decrease from a year earlier, with the FY2026 full-year figure at $318.9 million, up 7.76% from the prior year.
• Cash & Equivalents declined to $265.4 million in Q2 2026 per HQY's latest filing, from $318.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $404.0 million in Q1 2024 and bottomed at $161.2 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $289.1 million (2023), against an average of $275.8 million.
• Across the five-year window, Cash & Equivalents sank 78.11% in 2022 and jumped 64.14% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $210.2 million in 2022, then jumped by 58.93% to $334.1 million in 2023, then retreated by 3.56% to $322.2 million in 2024, then declined by 4.01% to $309.3 million in 2025, then declined by 14.19% to $265.4 million in 2026.
• Per Business Quant, the three latest HQY Cash & Equivalents figures stand at $265.4 million (Q2 2026), $318.9 million (Q1 2026), and $309.3 million (Q4 2025).